Paper39779554
Targeting PD-1 in Squamous Cell Carcinoma: Flavonoid-based Therapeutics Unveiled through in silico and in vitro Approaches.
Sharma N and 3 others. Curr Comput Aided Drug Des, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Targeting PD-1 in Squamous Cell Carcinoma: Flavonoid-based Therapeutics Unveiled through in silico and in vitro Approaches. Papers, record 39779554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39779554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting PD-1 in Squamous Cell Carcinoma: Flavonoid-based Therapeutics Unveiled through in silico and in vitro Approaches.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Flavonoids | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Molecular Docking Simulation | |
| Cell Line, Tumor | |
| Molecular Dynamics Simulation | |
| Computer Simulation |
Source PubMed
References86
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27373242 | Immune checkpoint inhibitors: a milestone in the treatment of melanoma. | J Dtsch Dermatol Ges | 2016 | https://conductscience.org/library/papers/27373242 | PubMed |
| 2 | 35646967 | Investigating Cutaneous Squamous Cell Carcinoma in vitro and in vivo: Novel 3D Tools and Animal Models. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35646967 | PubMed |
| 3 | 30243819 | [Beyond actinic keratoses: Field cancerization of the skin]. | Ann Dermatol Venereol | 2018 | https://conductscience.org/library/papers/30243819 | PubMed |
| 4 | 30238167 | Dermatoscopy of Neoplastic Skin Lesions: Recent Advances, Updates, and Revisions. | Curr Treat Options Oncol | 2018 | https://conductscience.org/library/papers/30238167 | PubMed |
| 5 | 30206456 | Outdoor work as a risk factor for high-grade cutaneous squamous cell carcinoma of the head and neck. | Postepy Dermatol Alergol | 2018 | https://conductscience.org/library/papers/30206456 | PubMed |
| 6 | 32852235 | Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma. | Expert Rev Anticancer Ther | 2020 | https://conductscience.org/library/papers/32852235 | PubMed |
| 7 | 21810686 | Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21810686 | PubMed |
| 8 | 11786562 | Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. | J Clin Oncol | 2002 | https://conductscience.org/library/papers/11786562 | PubMed |
| 9 | 28964539 | Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. | J Am Acad Dermatol | 2017 | https://conductscience.org/library/papers/28964539 | PubMed |
| 10 | 32004792 | Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. | Eur J Cancer | 2020 | https://conductscience.org/library/papers/32004792 | PubMed |
| 11 | 24879468 | Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature. | Am J Clin Oncol | 2016 | https://conductscience.org/library/papers/24879468 | PubMed |
| 12 | 28252823 | Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes. | Head Neck | 2017 | https://conductscience.org/library/papers/28252823 | PubMed |
| 13 | 33572373 | Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. | Biomedicines | 2021 | https://conductscience.org/library/papers/33572373 | PubMed |
| 14 | 23945592 | Signatures of mutational processes in human cancer. | Nature | 2013 | https://conductscience.org/library/papers/23945592 | PubMed |
| 15 | 25765070 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science | 2015 | https://conductscience.org/library/papers/25765070 | PubMed |
| 16 | 26788324 | Novel technologies and emerging biomarkers for personalized cancer immunotherapy. | J Immunother Cancer | 2016 | https://conductscience.org/library/papers/26788324 | PubMed |
| 17 | 30837075 | Immunotherapy in Nonmelanoma Skin Cancer. | Actas Dermosifiliogr (Engl Ed) | 2019 | https://conductscience.org/library/papers/30837075 | PubMed |
| 18 | 28716069 | Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. | J Immunother Cancer | 2017 | https://conductscience.org/library/papers/28716069 | PubMed |
| 19 | 27151159 | Cancer immunotherapy: the beginning of the end of cancer? | BMC Med | 2016 | https://conductscience.org/library/papers/27151159 | PubMed |
| 20 | 31196207 | Combination of CTLA-4 and PD-1 blockers for treatment of cancer. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31196207 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 40386063 | Screening and identification of versican as a sensitive biomarker and potential therapeutic target in basal cell carcinoma. | Int J Med Sci | 2025 | https://conductscience.org/library/papers/40386063 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39779554
GET https://conductscience.org/api/papers/v1/39779554/references?page=2